Oncological short-term effects and adverse events of MRI-guided selective neoadjuvant radiochemotherapy for rectal cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1721-1728

  Maurer, Christoph A ^a   Mattiello, D ^a   Duwe, J ^a   Ruppert, R ^b   Ptok, H ^c   Strassburg, J ^d   Junginger, T ^e   Merkel, S ^f   Hermanek, P ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Municipial Hospital of Munich Neuperlach   (Germany)

^c Carl Thiem Hospital   (Germany)

^d Vivantes Clinic   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Acute side effects; Down staging; Radiotherapy; Rectal cancer; Response

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORBIDITY; NEOADJUVANT RADIOCHEMOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY; TUMOR REGRESSION; TUMOR VOLUME;

CHEMORADIOTHERAPY; COHORT STUDIES; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RADIOTHERAPY, IMAGE-GUIDED; RECTAL NEOPLASMS; REOPERATION;

EID: 84861503410     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Fleming FJ, Pahlman L and Monson JR: Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 54: 901-912, 2011.
2. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG and Goldberg RM: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22: 1785-1796, 2004. (Pubitemid 41095168)
3. Ulrich A, Weitz J and Büchler MW: Rectal cancer. How much radiotherapy do surgery patients need? Chirurg 80: 266-73, 2009 (in German).
4. Heald RJ and Daniels IR: Rectal cancer management: Europe is ahead. Recent Results Cancer Res 165: 75-81, 2005.
5. Junginger Th, Hermanek P, Oberholzer K and Schmidberger H: Rectal carcinoma: Is too much neoadjuvant therapy performed? Proposals for a more selective MRI-based indication. Zentralbl Chir 131: 275-284, 2006 (in German). (Pubitemid 44407069)
6. Smith N and Brown G: Preoperative staging of rectal cancer. Acta Oncol 47: 20-31, 2008.
7. Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP, Bourne MW and Williams GT: Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 211: 215-222, 1999. (Pubitemid 29161754)
8. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW and Williams GT: Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90: 355-364, 2003. (Pubitemid 36324117)
9. Beets-Tan RGH and Beets GL: Rectal cancer: Review with emphasis on MRI imaging. Radiology 232: 335-346, 2004. (Pubitemid 38971269)
10. Brown G and Daniels JR: Preoperative staging of rectal cancer: the MERCURY research project. Recent Results Cancer Res 105: 58-74, 2005.
11. Lahaye MJ, Engelen SME, Nelemans PJ, Beets GL, van de Velde CJ, van Engelshoven JM and Beets-Tan RG: Imaging für predicting the risk factors - the circumferential resection margin and nodal disease - of local recurrence in rectal cancer: a meta-analysis. Sem Ultrasound CT MRI 26: 259-268, 2005. (Pubitemid 41111583)
12. Hermanek P, Junginger Th, Merkel S and Oberholzer K: High-reolution magnetic resonance imaging (MRI) in patients with rectal carcinoma: effectiveness in selection for neoadjuvant treatment. Recent Res Devel Cancer 8: 39-56, 2006.
13. MERCURY Study Group: Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br Med J 333: 779-784, 2006.
14. Maurer CA, Renzulli P, Kull C, Käser SA, Mazzucchelli L, Ulrich A and Büchler MW: The impact of the introduction of total mesorectal excision on local recurrence rate and survival in rectal cancer: long-term results. Ann Surg Oncol 18: 1899-1906, 2011.
15. Maughan NJ and Quirke P: Modern management of colorectal cancer - a pathologist's view. Scand J Surg 92: 11-19, 2003. (Pubitemid 36406631)
16. Nagtegaal ID, van de Velde CJH, Marijnen CAM, van Krieken JH and Quirke P; Dutch Colorectal Cancer Group; Pathology Review Committee.: Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 23: 9257-9264, 2005.
17. Quirke P and Morris E: Reporting colorectal cancer. Histopathology 50: 103-112, 2007. (Pubitemid 44953402)
18. Merkel S, Hohenberger W and Hermanek P: Intra-operative local tumor cell dissemination in rectal carcinoma surgery: effect of operation principles and neoadjuvant therapy. Chirurg 81: 719- 727, 2010 (in German).
19. Glynne-Jones R, Mawdsley S, Pearce T and Buyse M: Alternative clinical end points in rectal cancer - Are we getting close? Ann Oncol 17: 1239-1248, 2006. (Pubitemid 44288215)
20. Glynne-Jones R, Mawdsley S and Novell JR: The clinical significance of the circumferential resection margin following preoperative pelvic chemoradiotherapy in rectal cancer: Why we need a common language. Colorectal Dis 8: 800-807, 2006. (Pubitemid 44541712)
21. Nagtegaal ID and Quirke P: What is the role for the circumferential margin in the modern treatment for rectal cancer? J Clin Oncol 26: 303-312, 2008.
22. Strassburg J, Ruppert R, Ptok H, Maurer C, Junginger T, Merkel S and Hermanek P: MRT-based indication for neoadjuvant radiochemotherapy in rectal cancer: Interim results of a prospective multicentre observational study. Ann Surg Oncol 18: 2790-2799, 2011.
23. Sobin LH and Wittekind C (eds.).: UICC International Union against Cancer, TNM Classification of Malignant Tumours, sixth edition. Wiley-Liss, New York, pp. 72-76, 2002.
24. Dworak O, Keilholz L and Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23, 1997. (Pubitemid 27138353)
25. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R and Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy. J Clin Oncol 23: 8688-8696, 2005. (Pubitemid 46211512)
26. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF and Quirke P: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344: 707-11, 1994. (Pubitemid 24281421)
27. Wolthuis A, Penninckx F and Haustemans K: Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation. Ann Surg Oncol 18: 684-690, 2011.
28. Leibold T, Shia J, Ruo L, Akhurst T, Gollub MJ, Ginsberg MS, Larson S, Riedel E, Wong WD and Guillem JG: Prognostic implications of the distribution of lymph nodes metastasis in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol 26: 2106-2111, 2008.
29. Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W and Sauer R: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25: 110-117, 2007. (Pubitemid 350003058)
30. Park YJ, Oh BR, Lim SW, Huh JW, Joo JK, Kim YJ and Kim HR: Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol 26: 279-286, 2010.
31. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D and Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol 12: 111-116, 2005. (Pubitemid 40486618)
32. Rosenberg R, Engel J, Bruns C, Heitland W, Hermes N, Jauch KW, Kopp R, Pütterich E, Ruppert R, Schuster T, Friess H and Hölzel D: The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg 251: 1073-1078, 2010.
33. Kuo LJ, Liu MC, Jian JJM, Horng CF, Cheng TI, Chen CM, Fang WT and Chung YL: Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 14: 2766-2772, 2007.
34. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, MahéMA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C and Conroy T: Comparison of two neoadjuvent chemotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28: 1638- 1644, 2010.
35. Wang H, Safar B, Wexner SD, Denoya P and Berho M: The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy. Dis Colon Rectum 52: 1767-1773, 2009.
36. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr., Campos FG, Kiss DR and Gama- Rodrigues J: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240: 711-717; discussion 717-718, 2004.
37. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne- Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS and La Torre G: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72: 99-107, 2008.
38. Ceelen W. Fierens K, Van Nieuwenhore Y and Pattyn P: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: A systematic review and meta-analysis. Int J Cancer 124: 2966-2972, 2009.
39. Latkauskas T, Paskauskas S, Dambrauskas Z, Gudaityte J, Saladzinskas S, Tamelis A and Pavalkis D: Preoperative chemoradiation vs. radiation alone for stage II and III resectable rectal cancer: a meta-analysis. Colorectal Dis 12: 1075-1083, 2010.
40. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr., Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG and Beets GL: Longterm outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11: 835-844, 2010.
41. Rödel C and Sauer R: Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 183: 227-235, 2007. (Pubitemid 46725993)
42. Minsky BD and Guillem JG: Multidisciplinary management of resectable rectal cancer. New developments and controversies. Oncology 22: 1430-1437, 2008.
43. Swellengrebel HAM, Marijnen CAM, Verwaal VJ, Vincent A, Heuff G, Gerhards MF, van Geloven AA, van Tets WF, Verheij M and Cats A: Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 93: 418-426, 2011.
44. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P and Gerard JP: Influence of the interval between preoperative radiation therapy and surgery on down staging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R 90-01 Randomized Trial. J Clin Oncol 17: 2396-2402, 1999. (Pubitemid 29368238)
45. Tulchinski H, Shmueli E, Figer A, Klausner JM and Rabau M: An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 15: 2661-2667, 2008.
46. Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC and Fazio VW: Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 250: 582-589, 2009.
47. Stein DE, Mahmoud NN, Anné PR, Rose DG, Isenberg GA, Goldstein SD, Mitchell E and Fry RD: Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve down-staging of rectal carcinoma. Dis Colon Rectum 46: 448-453, 2003. (Pubitemid 36428037)
48. Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Ojerskog B, Damber L and Johansson R: The Swedish Rectal Cancer Registry. Br J Surg 94: 1285-1292, 2007. (Pubitemid 47584780)
49. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
50. Ulrich A, Weitz J, Slodczyk M, Koch M, Jaeger D, Münter M and Büchler MW: Neoadjuvant treatment does not influence perioperative outcome in rectal cancer surgery. Int J Radiat Oncol Biol Phys 75: 129-136, 2009.
51. Paun BC, Cassie S, MacLean AR, Dixon E and Buie WD: Postoperative complications following surgery for rectal cancer. Ann Surg 251: 807-818, 2010.
52. Fiorica F, Cartei F, Licata A, Enea M, Ursino S, Colosimo C and Cammà C: Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev 36: 539-549, 2010.
53. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Rugge M, Sinigaglia G, Rossi E, Compostella A, Toppan P, Agostini M and Monfardini S: Role of neoadjuvant treatment in cT3N0M0 rectal cancer. Anticancer Res 28(6B): 4129-4135, 2008.